Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

NCT04545762 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Refractory Non-Hodgkin Lymphoma
Burkitt Lymphoma
Mantle Cell Lymphoma
Follicular Lymphoma
Lymphoplasmacytic Lymphoma
Primary Mediastinal Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Small Lymphocytic Lymphoma
Transformed Lymphoma
Non-Hodgkin Lymphoma

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: anti-CD19 CAR-T cells

Sponsor

C. Babis Andreadis

Collaborators

[object Object]